Detection of anti-yellow fever virus immunoglobulin M antibodies at 3-4 years following yellow fever vaccination

American Journal of Tropical Medicine and Hygiene

Volumn 87, Issue 6, 2012, Pages 1112-1115

  Gibney, Katherine B ^a,b   Edupuganti, Srilatha ^a,c   Panella, Amanda J ^a,d   Kosoy, Olga I ^a,d   Delorey, Mark J ^a,d   Lanciotti, Robert S ^a,d   Mulligan, Mark J ^a,c   Fischer, Marc ^a,d   Staples, J Erin ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c Centers for Disease Control and Prevention ^*

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI YELLOW FEVER VIRUS IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFECTION PREVENTION; MALE; TRAVEL; VACCINATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; TIME FACTORS; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

YELLOW FEVER VIRUS;

EID: 84871544907     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.12-0182     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1-27.
2. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk of yellow fever. Lancet Infect Dis 11: 622-632.
3. Monath TP, Teuwen D, Cetron M, 2008. Yellow fever vaccine. Plotkin S, Orenstein W, Offit P, eds. Vaccines. Fifth edition. China: Elsevier, 959-1055.
4. Monath TP, 1971. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 93: 122-129.
5. Groot H, Riberiro RB, 1962. Neutralizing and hemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 27: 699-707.
6. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900. (Pubitemid 12155776)
7. Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT, 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38: 1823-1826. (Pubitemid 30253923)
8. Beaty BJ, Calisher CH, Shope RE, 1995. Arboviruses. Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Seventh edition. Washington, DC: American Public Health Association, 189-212.
9. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R, 2008. Human effector and memory CD8 + T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
10. Darsie R, Ward R, 2005. Identification and Geographical Distribution of the Mosquitoes of North America, North of Mexico. Gainesville, FL: University Press of Florida.
11. de Melo AB, da Silva Mda P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739-747.
12. Nogueira R, Schatzmayr H, Miagostovich M, Cavalcanti S, de Carvalho R, 1992. Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop Sao Paulo 34: 447-450.
13. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418-427. (Pubitemid 19117542)
14. Lhuillier M, Sarthou J-L, 1983. Anti-yellow fever IgM in the diagnosis and epidemiological surveillance of yellow fever. Ann Virol 134E: 349-359.
15. Kuno G, 2001. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its occurrence and impacts. Rev Med Virol 11: 165-190. (Pubitemid 32510201)
16. Martínez MJ, Vilella A, Pumarola T, Roldan M, Sequera VG, Vera I, Hayes EB, 2011. Persistence of yellow fever vaccine RNA in urine. Vaccine 29: 3374-3376.
17. Penna HA, Bittencourt A, 1943. Persistence of yellow fever virus in brains of monkeys immunized by cerebral inoculation. Science 97: 448-449.
18. Gould EA, Buckley A, Cane PA, Higgs S, Cammack N, 1989. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol 70: 1889-1894. (Pubitemid 19170217)
19. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B, 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
20. Meurman OH, 1978. Persistence of immunoglobulin G and immunoglobulin M antibodies after postnatal rubella infection determined by solid-phase radioimmunoassay. J Clin Microbiol 7: 34-38. (Pubitemid 8270325)
21. Edelman R, Schneider RJ, Vejjajiva A, Pornpibul R, Voodhikul P, 1976. Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. Am J Trop Med Hyg 25: 733-738.
22. Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Toluo H, Receveur MC, Pistone T, Rambert J, Moynet D, Mossalayi D, 2009. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 9: 200-206.
23. McAdam AJ, Farkash EA, Gewurz BE, Sharpe AH, 2000. B7 costimulation is critical for antibody class switching and CD8+ cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus. J Virol 74: 203-208. (Pubitemid 30002899)
24. Fuse S, Obar JJ, Bellfy S, Leung E, Zhang W, Usherwood EJ, 2006. CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol 80: 9159-9170. (Pubitemid 44359988)
25. Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, Poneprasert B, Fukunaga T, 1994. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 38: 951-955.
26. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159-167. (Pubitemid 28419278)